InMed Pharmaceuticals Provides Update On INM-089 In The Treatment Of Dry Age-Related Macular Degeneration; Small Molecule Drug Acting As A Preferential Signaling Ligand For CB1/CB2
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration
● Small molecule drug acting as a preferential signaling ligand for CB1/CB2
● Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model